BioPorto Total Liabilities
BioPorto total liabilities. Based on the latest financial reports, BioPorto (BIOPOR) has total liabilities worth Dkr26.84 Million DKK (≈ $4.20 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BIOPOR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BioPorto (1999–2025)
Total liabilities of BioPorto from 1999 to 2025. This chart illustrates how BioPorto's total liabilities have evolved over time, based on quarterly financial data.
BioPorto Competitors by Total Liabilities
The table below lists competitors of BioPorto ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Patriot One Technologies Inc
F:0PL
|
Germany | €10.94 Million |
|
HyVision System. Inc
KQ:126700
|
Korea | ₩50.51 Billion |
|
Vascon Engineers Limited
NSE:VASCONEQ
|
India | Rs12.12 Billion |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩76.26 Billion |
|
Pierce Group AB
ST:PIERCE
|
Sweden | Skr452.00 Million |
|
Tongyang
KO:001520
|
Korea | ₩689.99 Billion |
|
Morn Sun Feed Mill Corp
TWO:1240
|
Taiwan | NT$753.54 Million |
|
Associated Capital Group Inc
NYSE:AC
|
USA | $38.70 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down BioPorto's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BIOPOR asset base.
Liquidity & Leverage Metrics
BioPorto Total Liabilities Ratios Explained
BioPorto total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioPorto's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioPorto (1999–2025)
The table below shows the annual total liabilities of BioPorto from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr30.17 Million ≈ $4.72 Million |
+6.87% |
| 2024-12-31 | Dkr28.23 Million ≈ $4.42 Million |
-4.78% |
| 2023-12-31 | Dkr29.65 Million ≈ $4.64 Million |
-22.82% |
| 2022-12-31 | Dkr38.42 Million ≈ $6.01 Million |
+8.86% |
| 2021-12-31 | Dkr35.29 Million ≈ $5.52 Million |
-10.37% |
| 2020-12-31 | Dkr39.37 Million ≈ $6.16 Million |
+126.81% |
| 2019-12-31 | Dkr17.36 Million ≈ $2.72 Million |
+73.53% |
| 2018-12-31 | Dkr10.00 Million ≈ $1.57 Million |
+4.91% |
| 2017-12-31 | Dkr9.54 Million ≈ $1.49 Million |
+50.17% |
| 2016-12-31 | Dkr6.35 Million ≈ $993.50K |
+40.86% |
| 2015-12-31 | Dkr4.51 Million ≈ $705.31K |
-47.29% |
| 2014-12-31 | Dkr8.55 Million ≈ $1.34 Million |
-4.76% |
| 2013-12-31 | Dkr8.98 Million ≈ $1.40 Million |
-53.54% |
| 2012-12-31 | Dkr19.33 Million ≈ $3.02 Million |
+11.65% |
| 2011-12-31 | Dkr17.31 Million ≈ $2.71 Million |
-2.00% |
| 2010-12-31 | Dkr17.66 Million ≈ $2.76 Million |
+267.48% |
| 2009-12-31 | Dkr4.81 Million ≈ $752.09K |
+31.52% |
| 2008-12-31 | Dkr3.65 Million ≈ $571.85K |
-17.79% |
| 2007-12-31 | Dkr4.45 Million ≈ $695.61K |
-80.17% |
| 2006-12-31 | Dkr22.42 Million ≈ $3.51 Million |
+27.96% |
| 2005-12-31 | Dkr17.52 Million ≈ $2.74 Million |
+22.50% |
| 2004-12-31 | Dkr14.30 Million ≈ $2.24 Million |
-0.69% |
| 2003-12-31 | Dkr14.40 Million ≈ $2.25 Million |
+518.60% |
| 2002-12-31 | Dkr2.33 Million ≈ $364.23K |
-41.90% |
| 2001-12-31 | Dkr4.01 Million ≈ $626.92K |
-38.95% |
| 2000-12-31 | Dkr6.56 Million ≈ $1.03 Million |
-52.31% |
| 1999-12-31 | Dkr13.76 Million ≈ $2.15 Million |
-- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more